L M E van Erp1, H Maurice-Stam2, L C M Kremer3, W J E Tissing4, H J H van der Pal1, A C H de Vries5, M M van den Heuvel-Eibrink5, B A B Versluys6, J J Loonen7, D Bresters8, M Louwerens9, M van der Heiden-van der Loo10, M H van den Berg11, C M Ronckers12, A L L F van der Kooi13, M van Gorp1, E van Dulmen-den Broeder14, M A Grootenhuis1. 1. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. 2. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Electronic address: h.maurice-stam@prinsesmaximacentrum.nl. 3. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. 4. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Beatrix Children's Hospital/University of Groningen/University Medical Center Groningen, Groningen, the Netherlands. 5. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Sophia Children's Hospital/Erasmus Medical Center, Rotterdam, the Netherlands. 6. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, the Netherlands. 7. Radboud University Medical Center, Nijmegen, the Netherlands. 8. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Leiden University Medical Center, Leiden, the Netherlands. 9. Leiden University Medical Center, Leiden, the Netherlands. 10. Dutch Childhood Oncology Group, Utrecht, the Netherlands. 11. Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Paediatrics, Amsterdam, the Netherlands. 12. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Brandenburg Medical School, Institute of Biostatistics and Registry Research, Neuruppin, Germany. 13. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Erasmus MC, University Medical Centre, Rotterdam, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology. 14. Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Amsterdam UMC/location VUmc, Amsterdam, the Netherlands.
Abstract
AIM: To investigate the health-related quality of life (HRQOL) of Dutch adult childhood cancer survivors (CCS) and to identify risk factors of impaired HRQOL. METHODS: Adult CCS (age >18, diagnosed <18, ≥5 years since diagnosis) from the Dutch LATER registry completed the Medical Outcome Study Short Form 36 (SF-36) to measure HRQOL and provided sociodemographic characteristics. Age-adjusted mean SF-36 scale scores of CCS were compared to the Dutch general population for men and women separately using t-tests, with effect size d. Multivariate logistic regression models were built to identify sociodemographic and cancer-related risk factors for impaired physical and mental HRQOL. RESULTS: Both male and female CCS (N = 2301, mean age = 35.4 years, 49.6% female) reported significantly (p ≤ .005) worse HRQOL than the general population on almost all scales of the SF-36 (-.11 ≤ d ≤ -.56). Largest differences were found on vitality and general health perceptions. Significant risk factors (p ≤ .05) for impaired physical HRQOL were female sex, older age at diagnosis, not having a partner, low educational attainment, disease recurrence and exposure to radiotherapy, specifically to lower extremity radiation. Odds ratios (ORs) ranged from 1.6 to 3.7. Significant risk factors for impaired mental HRQOL were age 26-35 years, male sex, not having a partner and low educational attainment. ORs ranged from 1.3 to 2.0. CONCLUSION: Adult CCS had worse HRQOL than the general population. CCS most at risk were those with low educational attainment and without a partner. Adult CCS could benefit from routine surveillance of their HRQOL. Special attention for CCS' vitality and health perceptions and beliefs is warranted.
AIM: To investigate the health-related quality of life (HRQOL) of Dutch adult childhood cancer survivors (CCS) and to identify risk factors of impaired HRQOL. METHODS: Adult CCS (age >18, diagnosed <18, ≥5 years since diagnosis) from the Dutch LATER registry completed the Medical Outcome Study Short Form 36 (SF-36) to measure HRQOL and provided sociodemographic characteristics. Age-adjusted mean SF-36 scale scores of CCS were compared to the Dutch general population for men and women separately using t-tests, with effect size d. Multivariate logistic regression models were built to identify sociodemographic and cancer-related risk factors for impaired physical and mental HRQOL. RESULTS: Both male and female CCS (N = 2301, mean age = 35.4 years, 49.6% female) reported significantly (p ≤ .005) worse HRQOL than the general population on almost all scales of the SF-36 (-.11 ≤ d ≤ -.56). Largest differences were found on vitality and general health perceptions. Significant risk factors (p ≤ .05) for impaired physical HRQOL were female sex, older age at diagnosis, not having a partner, low educational attainment, disease recurrence and exposure to radiotherapy, specifically to lower extremity radiation. Odds ratios (ORs) ranged from 1.6 to 3.7. Significant risk factors for impaired mental HRQOL were age 26-35 years, male sex, not having a partner and low educational attainment. ORs ranged from 1.3 to 2.0. CONCLUSION: Adult CCS had worse HRQOL than the general population. CCS most at risk were those with low educational attainment and without a partner. Adult CCS could benefit from routine surveillance of their HRQOL. Special attention for CCS' vitality and health perceptions and beliefs is warranted.
Authors: Adriaan Penson; Iris Walraven; Ewald Bronkhorst; Heleen Maurice-Stam; Martha A Grootenhuis; Margriet Van der Heiden-van der Loo; Wim J E Tissing; Helena J H Van der Pal; Andrica C H De Vries; Dorine Bresters; Cécile Ronckers; Marry M Van den Heuvel; Sebastian J C M M Neggers; Birgitta A B Versluys; Marloes Louwerens; Saskia M F Pluijm; Leontien C M Kremer; Nicole Blijlevens; Eline Van Dulmen-den Broeder; Hans Knoop; Jacqueline Loonen Journal: Cancers (Basel) Date: 2022-06-09 Impact factor: 6.575
Authors: Marloes van Gorp; Loes M E van Erp; Anne Maas; Leontien C M Kremer; Eline van Dulmen-den Broeder; Wim J E Tissing; Jacqueline J Loonen; Helena J H van der Pal; Andrica C H de Vries; Marry M van den Heuvel-Eibrink; Cécile M Ronckers; Dorine Bresters; Marloes Louwerens; Margriet van der Heiden-van der Loo; Gea A Huizinga; Heleen Maurice-Stam; Martha A Grootenhuis Journal: Cancer Date: 2021-11-02 Impact factor: 6.921